Nov 18, 2019 / 09:30PM GMT
Operator
Greetings. Welcome to the AHA investor discussion conference call. (Operator Instructions) Please note this conference is being recorded.
I would now like to turn the conference over to your host, Elisabeth Schwartz. Thank you. You may begin.
Elisabeth Schwartz - Amarin Corporation plc - Senior Director of IR
Welcome to today's discussion to explore for our investment community the several important new data sets and analyses related to Vascepa and REDUCE-IT as presented at the 2019 American Heart Association's Scientific Sessions here in Philadelphia.
Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding Vascepa clinical data and cost-effectiveness analyses and expectations regarding the application of these data to clinical use, in reimbursement and regulatory settings and to commercial prospects for Vascepa.
Amarin Corporation PLC O Webcast Discussion Of Presented Data at American Heart Assocition's 2019 Scientific Sessions Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
